Anna Eramo, MD, Psychiatrist, has been our Chief Medical Officer since Sep 2020. Dr. Eramo joined the Company from Lundbeck, where she led US Clinical and Medical Affairs with primary responsibilities extending across Lundbeck’s entire US neurology and psychiatric portfolio of products, including brexpriprazole, vortioxetine, and Abilify Maintena. Dr. Eramo holds both an academic degree in medicine and a specialty degree in psychiatry and psychotherapy from the University Medical School of Naples, Italy.
